Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Teva
US Department of Justice
Mallinckrodt
Citi
Johnson and Johnson

Generated: September 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,592,207

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,592,207 protect, and when does it expire?

Patent 9,592,207 protects SPRAVATO and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 9,592,207
Title:Intranasal administration of ketamine to treat depression
Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
Inventor(s): Charney; Dennis S. (New York, NY), Mathew; Sanjay J. (New York, NY), Manji; Husseini K. (Rockville, MD), Zarate; Carlos A. (Rockville, MD), Krystal; John H. (New Haven, CT)
Assignee: Icahn School of Medicine at Mount Sinai (New York, NY) Yale University (New Haven, CT) The United States of America, as represented by The Secretary, Department of Health and Human Services (Washington, DC)
Application Number:14/306,382
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,592,207

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Pharms SPRAVATO esketamine hydrochloride SPRAY;NASAL 211243-001 Mar 5, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,592,207

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007229866 ➤ Sign Up
China 101466364 ➤ Sign Up
European Patent Office 2012762 ➤ Sign Up
Israel 194198 ➤ Sign Up
Japan 2009530385 ➤ Sign Up
South Korea 20090029690 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2007111880 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Teva
McKinsey
Johnson and Johnson
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.